Zynerba Pharmaceuticals, Inc. received orphan drug designation from the U.S. Food and Drug Administration (FDA) for cannabidiol (CBD) for use in treating 22q11.2 deletion syndrome (22q). 22q is a rare condition featuring physical abnormalities and debilitating neuropsychiatric and behavioral symptoms including anxiety, withdrawn behavior, and social interaction problems. The resulting drug therapy will be called Zygel CBD gel.

As the second most common chromosomal disorder after Down syndrome, 22q is caused by a small missing piece of the 22nd chromosome. It is considered a midline condition, with physical symptoms including characteristic palate abnormalities, heart defects, immune dysfunction, and . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
If you are already a member, log in to your account to access this resource and more.

You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Autism & I/DD

Intellectual and developmental disabilities (I/DD) are a physical and/or cognitive impairments that occur before the age of 22. Autism spectrum disorder is generally considered a type of developmental disability that affects behaviour and communication. The autism and I/DD market provides supports and health care services to these populations. Over the past decade, there has been an increase in the changes and challenges affecting I/DD and autism markets—the move to managed care and value-based care, the shift away from residential treatment, the increasing emphasis on consumer-directed care, and new workforce challenges.


Latest Resources
See All
The Modified Checklist for Autism in Toddlers (M-CHAT), a widely used screening tool for early detection of autism spectrum disorder (ASD) in children ages 16 to 30 months, missed 38% of high-risk toddlers who were later diagnosed with ASD, according to a study of Swedish national health data. The study analyzed 2,178 high-risk children born between 2013 and 2019 who were screened with the M-CHAT at approximately age 2 and followed through age 9 for… Read